Eli Lilly Stock Quote Latest News and Market Insights

Eli Lilly stock has been on a rollercoaster ride in recent years, with its price fluctuating due to various market and economic factors.

The company's stock price has been influenced by its strong pipeline of new drugs, including its COVID-19 treatment, which has been in high demand.

Investors are closely watching the company's financial performance, including its revenue growth and profitability.

Eli Lilly's stock has historically been a stable investment option, with a relatively low volatility compared to other pharmaceutical stocks.

For another approach, see: Stock Price

Eli Lilly's revenue in 2023 was $34.12 billion, a 19.56% increase from the previous year.

The company's earnings were $5.24 billion, but this represents a decrease of 16.08% compared to the previous year.

Eli Lilly's current share price is $808.17, which is a significant increase from its 52-week low of $637.00.

The company's beta is 0.41, indicating a relatively low level of volatility. Over the past year, the stock has increased by 25.30%.

Here are some key financial metrics for Eli Lilly:

The company's price-to-sales ratio is 17.88, and its price-to-earnings ratio is 77.23.

For your interest: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

Eli Lilly's revenue grew by 19.56% in 2023 to $34.12 billion, a significant increase from the previous year's $28.54 billion.

In 2024, the company lowered its full-year revenue forecast, which led to a sharp decline in stock prices. The shares fell sharply in trade on Tuesday.

Eli Lilly's earnings were $5.24 billion in 2023, a decrease of -16.08% compared to the previous year. This decline in earnings contributed to the company's weaker sales outlook.

The company's stock price has been affected by its sales outlook, with shares falling on Tuesday and remaining under the microscope. Eli Lilly's stock price has been volatile, with a 1 Month Change of 3.19% and a 3 Month Change of -10.56%.

Here's a summary of Eli Lilly's stock performance over the past year:

The company's stock price has shown significant growth over the long term, with a 5 Year Change of 473.17% and a Change since IPO of 28,674.90%.

Eli Lilly recently announced that the US FDA has approved its bowel disease drug to treat adults with moderate-to-severe Crohn's disease. This is a significant development for the company.

The drug, Omvoh, showed significant improvement in clinical remission and endoscopic response in a pivotal Phase 3 trial. Patients who took the drug experienced a notable improvement in their condition.

Eli Lilly has also made some adjustments to its sales forecast, reducing its fourth-quarter sales guidance by 5%. This new forecast stands at $13.5 billion, which is $400 million below the low end of the company's prior guidance.

You might like: Eli Fross Birthday

The US FDA has approved Eli Lilly's drug for adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease.

This approval marks a significant development for patients suffering from Crohn's disease, who can now have access to a new treatment option.

The drug, Omvoh, was tested in the pivotal Phase 3 VIVID-1 trial, where patients experienced significant improvement in clinical remission and endoscopic response at one year.

By achieving clinical remission, patients can expect a reduction in symptoms and an improvement in their overall quality of life.

In the trial, patients who achieved clinical remission also showed significant improvement in endoscopic response, indicating a reduction in inflammation and damage to the bowel lining.

Eli Lilly reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion.

This new forecast is $400 million below the low end of the company's prior guidance.

The reduced guidance includes $3.5 billion in expected revenue from various sources.

Eli Lilly's stock has been impacted by the tepid sales outlook, leading to a sharp decline in shares on Tuesday.

Shares could remain under the microscope as investors wait for the company's next move.

For your interest: How Do Stock Shares Work